Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies
02 Février 2016 - 2:00PM
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and
AbCellera have entered into a collaborative research agreement
whereby AbCellera will apply its high-throughput single cell
antibody platform for the discovery of rare monoclonal antibodies.
“We are pleased to work with AbCellera utilizing this company’s
novel biologics technology,” said Michael Hayden, MD, PhD,
President of Global R&D and Chief Scientific Officer at Teva.
“This agreement will be complementary to our existing antibody
discovery process with the potential to strengthen Teva’s
capabilities in novel biologics discovery.”
Under the terms of the agreement, AbCellera will receive an
upfront payment, research payments, and is eligible to receive
undisclosed downstream milestones associated with the development
and approval of therapeutic antibodies.
“These are tough problems that need new technologies to move
them forward. Our platform brings important advantages to enable
the discovery of rare antibodies with defined specificity and
functional activity against difficult membrane protein targets,”
said Dr. Carl Hansen, President and CEO of AbCellera. “We look
forward to a close collaboration with the team of scientists at
Teva, and are excited at the chance to help advance this important
program.”
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions to millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,000
molecules to produce a wide range of generic products in nearly
every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of
the central nervous system, including pain, as well as a strong
portfolio of respiratory products. Teva integrates its generics and
specialty capabilities in its global research and development
division to create new ways of addressing unmet patient needs by
combining drug development capabilities with devices, services and
technologies. Teva's net revenues in 2014 amounted to $20.3
billion. For more information, visit www.tevapharm.com.
About AbCellera Biologics Inc.
AbCellera is a privately held company that has developed a
high-throughput platform for the rapid discovery of therapeutic
antibodies directly from natural immune cells. The company’s
proprietary single cell technology can be applied across multiple
species and provides flexible assay formats to identify antibodies
with defined properties at a throughput of millions of B cells per
run. In addition to internal programs, AbCellera provides
pharmaceutical and biotechnology partners with access to
state-of-the-art antibody discovery capabilities to advance and
accelerate therapeutic development. For more information, visit
http://www.abcellera.com.
Teva's Safe Harbor Statement under the U. S. Private
Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are
based on management’s current beliefs and expectations and involve
a number of known and unknown risks and uncertainties that could
cause our future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include
risks relating to: our ability to develop and commercialize
additional pharmaceutical products; competition for our specialty
products, especially Copaxone® (including competition from
orally-administered alternatives, as well as from generic
equivalents such as the recently launched Sandoz product) and our
ability to continue to migrate users to our 40 mg/mL version and
maintain patients on that version; our ability to identify and
successfully bid for suitable acquisition targets or licensing
opportunities (such as our pending acquisitions of Allergan’s
generic business and Rimsa), or to consummate and integrate
acquisitions; the possibility of material fines, penalties and
other sanctions and other adverse consequences arising out of our
ongoing FCPA investigations and related matters; our ability to
achieve expected results from the research and development efforts
invested in our pipeline of specialty and other products; our
ability to reduce operating expenses to the extent and during the
timeframe intended by our cost reduction program; the extent to
which any manufacturing or quality control problems damage our
reputation for quality production and require costly remediation;
increased government scrutiny in both the U.S. and Europe of our
patent settlement agreements; our exposure to currency fluctuations
and restrictions as well as credit risks; the effectiveness of our
patents, confidentiality agreements and other measures to protect
the intellectual property rights of our specialty medicines; the
effects of reforms in healthcare regulation and pharmaceutical
pricing, reimbursement and coverage; governmental investigations
into sales and marketing practices, particularly for our specialty
pharmaceutical products; adverse effects of political or economic
instability, major hostilities or acts of terrorism on our
significant worldwide operations; interruptions in our supply chain
or problems with internal or third-party information technology
systems that adversely affect our complex manufacturing processes;
significant disruptions of our information technology systems or
breaches of our data security; competition for our generic
products, both from other pharmaceutical companies and as a result
of increased governmental pricing pressures; competition for our
specialty pharmaceutical businesses from companies with greater
resources and capabilities; the impact of continuing consolidation
of our distributors and customers; decreased opportunities to
obtain U.S. market exclusivity for significant new generic
products; potential liability in the U.S., Europe and other markets
for sales of generic products prior to a final resolution of
outstanding patent litigation; our potential exposure to product
liability claims that are not covered by insurance; any failure to
recruit or retain key personnel, or to attract additional executive
and managerial talent; any failures to comply with complex Medicare
and Medicaid reporting and payment obligations; significant
impairment charges relating to intangible assets, goodwill and
property, plant and equipment; the effects of increased leverage
and our resulting reliance on access to the capital markets;
potentially significant increases in tax liabilities; the effect on
our overall effective tax rate of the termination or expiration of
governmental programs or tax benefits, or of a change in our
business; variations in patent laws that may adversely affect our
ability to manufacture our products in the most efficient manner;
environmental risks; and other factors that are discussed in our
Annual Report on Form 20-F for the year ended December 31, 2014 and
in our other filings with the U.S. Securities and Exchange
Commission.
IR Contacts: |
Kevin C. Mannix |
United States |
(215) 591-8912 |
|
Ran Meir |
United States |
(215) 591-3033 |
|
Tomer Amitai |
Israel |
972 (3) 926-7656 |
PR Contacts: |
Iris Beck Codner |
Israel |
972 (3) 926-7687 |
|
Denise Bradley |
United States |
(215) 591-8974 |
|
Nancy Leone |
United States |
(215) 284-0213 |
AbCellera Contact: |
Kevin Heyries |
Canada |
(604) 827-4151 |
|
|
|
|
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024